Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North America and Europe.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 7, Boulevard Henri Becquerel, Gip Cyceron,france
- co****@****sis.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.op2lysis.com
- HQ
- Caen, Normandy
Op2lysis Questions
Op2Lysis's website is http://www.op2lysis.com
Op2Lysis's LinkedIn profile is https://fr.linkedin.com/company/op2lysis
Op2Lysis has
7 employees.
View email and phone details for 7
employees at Op2Lysis.
Op2Lysis's industry is
Biotechnology Research
Op2Lysis's top competitors are
Exo Biologics,
Seqalis,
Amyl Therapeutics,
Eyed Pharma,
Kiomed Pharma,
Abscint,
Syngulon,
Pdc*line Pharma,
White Raven,
Hyloris Pharmaceuticals.
Op2Lysis's support email address is contact@op2lysis.com
Op2Lysis's categories are Biotechnology Research
Op2Lysis's founding year is 2016
